ANAB insider transaction filings
ANAPTYSBIO, INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-07. Screen ANAB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Faga Daniel — President, CEO, Director | Grant/award (A): 53,334 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Lizzul Paul F. — Chief Medical Officer | Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Schmid John P. — Director | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Orwin John A — Director | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | RENTON HOLLINGS — Director | Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Murphy Christopher M. — Chief Financial Officer | Grant/award (A): 25,765 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Hughes Owen — Director | Grant/award (A): 11,250 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | GRAY SUSANNAH — Director | Grant/award (A): 11,250 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4/A | Faga Daniel — President, CEO, Director | Disposition to issuer (D): 11,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Faga Daniel — President, CEO, Director | Disposition to issuer (D): 11,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Disposition to issuer (D): 2,321 (derivative) @ $0 · Grant/award (A): 2,321 (derivative) @ $0 · Disposition to issuer (D): 9,200 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · +8 more | EDGAR |
| 2026-04-22 | 4 | Schmid John P. — Director | Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · +14 more | EDGAR |
| 2026-04-22 | 4 | Orwin John A — Director | Disposition to issuer (D): 3,311 (derivative) @ $0 · Grant/award (A): 3,311 (derivative) @ $0 · Disposition to issuer (D): 10,600 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 · Disposition to issuer (D): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · +4 more | EDGAR |
| 2026-04-22 | 4 | RENTON HOLLINGS — Director | Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · +14 more | EDGAR |
| 2026-04-01 | 4 | Schmid John P. — Director | Sale (S): 12,596 @ $55.71 · Sale (S): 7,527 @ $56.70 · Sale (S): 522 @ $57.40 | EDGAR |
| 2026-03-27 | 4 | Faga Daniel — President, CEO, Director | Grant/award (A): 34,300 · Sale (S): 510 @ $56.61 · Sale (S): 2,570 @ $57.91 · Sale (S): 3,662 @ $58.62 · Sale (S): 490 @ $59.62 · Sale (S): 550 @ $60.63 · +5 more | EDGAR |
| 2026-02-13 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 10,000 @ $29.70 · Sale (S): 10,000 @ $54 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Marquet Magda — Director | Option exercise (M): 11,000 @ $26.11 · Sale (S): 9,290 @ $48.12 · Sale (S): 1,710 @ $48.85 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Lizzul Paul F. — Chief Medical Officer | Option exercise (M): 8,525 · Sale (S): 3,650 @ $44.71 · Option exercise (M): 8,525 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Faga Daniel — President, CEO, Director | Option exercise (M): 26,838 · Sale (S): 14,281 @ $44.71 · Option exercise (M): 26,838 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | MULROY DENNIS — CHIEF FINANCIAL OFFICER | Option exercise (M): 6,700 · Sale (S): 2,515 @ $44.71 · Option exercise (M): 6,700 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 5,888 · Sale (S): 2,210 @ $44.71 · Option exercise (M): 5,888 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Ware J. Anthony — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Lizzul Paul F. — Chief Medical Officer | Option exercise (M): 6,145 · Sale (S): 2,235 @ $45.11 · Option exercise (M): 6,145 (derivative) @ $0 · Grant/award (A): 21,400 (derivative) @ $0 · Grant/award (A): 29,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Jain Rita — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Faga Daniel — President, CEO, Director | Option exercise (M): 17,850 · Sale (S): 9,202 @ $45.11 · Option exercise (M): 17,850 (derivative) @ $0 · Grant/award (A): 98,600 (derivative) @ $0 · Grant/award (A): 133,400 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Marquet Magda — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Schmid John P. — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Orwin John A — Director | Grant/award (A): 8,250 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | MULROY DENNIS — CHIEF FINANCIAL OFFICER | Option exercise (M): 5,245 · Sale (S): 1,908 @ $45.11 · Option exercise (M): 5,245 (derivative) @ $0 · Grant/award (A): 21,400 (derivative) @ $0 · Grant/award (A): 29,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 5,545 · Sale (S): 2,017 @ $45.11 · Sale (S): 5,281 @ $45.38 · Sale (S): 1,841 @ $46.13 · Sale (S): 500 @ $47.23 · Option exercise (M): 5,545 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-08 | 4 | FENTON DENNIS M — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | RENTON HOLLINGS — Director | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Lizzul Paul F. — Chief Medical Officer | Option exercise (M): 10,555 · Sale (S): 4,219 @ $43.26 · Option exercise (M): 10,555 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Faga Daniel — President, CEO, Director | Option exercise (M): 34,677 · Sale (S): 15,309 @ $43.26 · Option exercise (M): 34,677 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | MULROY DENNIS — CHIEF FINANCIAL OFFICER | Option exercise (M): 8,292 · Sale (S): 3,363 @ $43.26 · Option exercise (M): 8,292 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 7,287 · Sale (S): 2,983 @ $43.26 · Option exercise (M): 7,287 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Ware J. Anthony — Director | Sale (S): 3,900 @ $49.58 | EDGAR |
| 2025-12-23 | 4 | Lizzul Paul F. — Chief Medical Officer | Option exercise (M): 1,500 @ $18.50 · Sale (S): 1,500 @ $50 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Schmid John P. — Director | Other (J): 11,068 @ $51 | EDGAR |
| 2025-12-23 | 4 | MULROY DENNIS — CHIEF FINANCIAL OFFICER | Option exercise (M): 10,000 @ $20.16 · Sale (S): 10,000 @ $50 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 10,000 @ $14.02 · Sale (S): 10,000 @ $51 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | MULROY DENNIS — CHIEF FINANCIAL OFFICER | Option exercise (M): 10,000 @ $20.16 · Sale (S): 9,365 @ $44.62 · Sale (S): 6,360 @ $45.21 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 5,000 @ $14.02 · Option exercise (M): 7,500 @ $20.16 · Sale (S): 8,305 @ $44.68 · Sale (S): 4,195 @ $45.24 · Option exercise (M): 10,000 @ $14.02 · Sale (S): 10,000 @ $46 · +4 more | EDGAR |
| 2025-10-01 | 4 | LOUMEAU ERIC J — CHIEF LEGAL OFFICER | Option exercise (M): 5,000 @ $14.02 · Sale (S): 8,240 @ $29 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Orwin John A — Director | Option exercise (M): 1,300 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | RENTON HOLLINGS — Director | Option exercise (M): 10,231 @ $6.93 · Sale (S): 3,110 @ $19.44 · Sale (S): 7,121 @ $19.70 · Option exercise (M): 10,231 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | RENTON HOLLINGS — Director | Option exercise (M): 20,925 @ $6.93 · Sale (S): 7,250 @ $23.09 · Sale (S): 13,675 @ $23.82 · Option exercise (M): 20,925 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | RENTON HOLLINGS — Director | Sale (S): 3,015 @ $23.97 | EDGAR |
| 2025-06-20 | 4 | FENTON DENNIS M — Director | Sale (S): 3,015 @ $23.97 | EDGAR |
| 2025-06-17 | 4 | Jain Rita — Director | Option exercise (M): 7,330 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
Recent 8-K events — ANAPTYSBIO, INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-06-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-29 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-21 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-24 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ANAB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →